Syngene International Vows FY27 Turnaround as Promoter Signals End of CDMO Sector Headwinds
Syngene's promoter has committed to a turnaround by FY27, citing a recovery in demand and stabilization in global biotech funding cycles. The company aims to overcome recent growth plateaus by…
Read the full article2d agoen
You might also wanna read
Syngenis banks $4M pre-float to power AI-driven biotech platform
Perth biotech Syngenis Labs has banked an oversubscribed $4M pre-IPO raise to expand its AI-powered RNA platform and strengthen domestic gen
The Age·4d ago
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.
This could be a key move for future growth.
Bars·12d ago
Syngene FY26 profit falls 20%, revenue rises 3%
Annual report attributes decline to destocking by its largest biologics manufacturing client
thehindubusinessline.com·7d ago
Biogen's Q2 2026 Earnings: What to Expect
Barchart·7d ago
Biogena Group Invest Aktie: 25 Millionen für Direct-Market-Plus
Biogena Group Invest bereitet den Sprung in den Direct Market Plus vor. Der Salzburger Mikronährstoff-Spezialist setzt dabei auf eine deutli
aktiencheck.de
Biotech ist zurück: Diese Aktie führt die Rally an
Jahrelang ließen Anleger die Branche links liegen. Doch das hat sich geändert. Im Windschatten der KI-Rally kennt der Biotechnologiesektor k
aktiencheck.de
Comments
Sign in to join the conversation.
No comments yet. Be the first.